17 research outputs found
Patient characteristics.
<p>ACEI = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CA = catheter ablation; CCB = calcium channel blocker; LA = left atrium; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PBMV = percutaneous balloon mitral valvuloplasty; PCI = percutanous coronary intervention.</p
Predictors of long-term recurrence of AF.
<p>AF = atrial fibrillation; CI = confidence interval; ERAF = early recurrence of atrial fibrillation; HR = hazard ratio; LA = left atrial</p
Single-procedure success for patients with LA diameter<40 mm versus≥40 mm (A), with AF duration≤24 months versus>24 months (B), with ERAF versus without ERAF (C).
<p>Plus sign (+) indicates censored.</p
Long-term freedom from AF after single-procedure.
<p>(A) overall patients (B) patients specified by type of AF. Plus sign (+) indicates censored.</p
Kaplan-Meier analysis of long-term freedom from AF after the initial procedure.
<p>group 1: patients with LA diameter<40 mm and AF duration≤24 months and without ERAF; group 2 patients with LA diameter≥40 mm, AF duration>24 months and with ERAF. Plus sign (+) indicates censored.</p
Characteristics of patients underwent catheter ablation after surgery.
<p>AF = atrial fibrillation; AFL = atrial flutter; CA = catheter ablation; SR = sinus rhythm</p
Perioperative results.
<p>AF = atrial fibrillation; AFL = atrial flutter; ECV = electric cardioversion; GP = ganglionated plexi; ICU = intensive care unit; LAA = left atrial appendage; PTE = pulmonary thromboembolism.</p
Number of adverse events (AEs) reported.
Efforts to develop a range of HIV prevention products that can serve as behaviorally congruent viable alternatives to consistent condom use and oral pre-exposure prophylaxis (PrEP) remain crucial. MTN-035 was a randomized crossover trial seeking to evaluate the safety, acceptability, and adherence to three placebo modalities (insert, suppository, enema) prior to receptive anal intercourse (RAI). If participants had no RAI in a week, they were asked to use their assigned product without sex. We hypothesized that the modalities would be acceptable and safe for use prior to RAI, and that participants would report high adherence given their behavioral congruence with cleansing practices (e.g., douches and/or enemas) and their existing use to deliver medications (e.g., suppositories; fast-dissolving inserts) via the rectum. Participants (N = 217) were sexual and gender minorities enrolled in five different countries (Malawi, Peru, South Africa, Thailand, and the United States of America). Mean age was 24.9 years (range 18–35 years). 204 adverse events were reported by 98 participants (45.2%); 37 (18.1%) were deemed related to the study products. The proportion of participants reporting “high acceptability” was 72% (95%CI: 65% - 78%) for inserts, 66% (95%CI: 59% - 73%) for suppositories, and 73% (95%CI: 66% - 79%) for enemas. The proportion of participants reporting fully adherent per protocol (i.e., at least one use per week) was 75% (95%CI: 69% - 81%) for inserts, 74% (95%CI: 68% - 80%) for suppositories, and 83% (95%CI: 77% - 88%) for enemas. Participants fully adherent per RAI-act was similar among the three products: insert (n = 99; 58.9%), suppository (n = 101; 58.0%) and enema (n = 107; 58.8%). The efficacy and effectiveness of emerging HIV prevention drug depends on safe and acceptable delivery modalities that are easy to use consistently. Our findings demonstrate the safety and acceptability of, and adherence to, enemas, inserts, and suppositories as potential modalities through which to deliver a rectal microbicide.</div
Participants’ sociodemographic characteristics, overall and by site.
Participants’ sociodemographic characteristics, overall and by site.</p
Results from a linear mixed models with logistic link function estimating the odds ratio of reporting High (A) Acceptability to Study Product and (B) Adherence to Study product, for the Rectal Insert and Rectal Suppository, relative to the Rectal Enema, after accounting for site and sequence order.
Results from a linear mixed models with logistic link function estimating the odds ratio of reporting High (A) Acceptability to Study Product and (B) Adherence to Study product, for the Rectal Insert and Rectal Suppository, relative to the Rectal Enema, after accounting for site and sequence order.</p